Xvivo Perfusion ABXVIPF -1.32%91 Pretax Margin % is 17.78% as of Mar. 2026, which is 264% above its 10-year median of 4.89. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 70.87% on this metric.
The historical rank and industry rank for Xvivo Perfusion AB's Pretax Margin % or its related term are showing as below:
XVIPF'
s Pretax Margin % Range Over the Past 10 Years
Min: -31.84 Med: 4.89 Max: 24.31
Current: 11.44
XVIPF's Pretax Margin % is ranked better than 70.87% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.61
vs XVIPF: 11.44
Xvivo Perfusion AB (OTCPK:XVIPF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Xvivo Perfusion AB Pretax Margin % Related Terms
Xvivo Perfusion AB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XVIPF vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Pretax Margin % of 17.78% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Xvivo Perfusion AB and its competitors. This is 264% above median its historical median of 4.89. According to the industry distribution chart, Xvivo Perfusion AB ranks #238 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 29.1%.
Is Xvivo Perfusion AB's Pretax Margin % too high?
Xvivo Perfusion AB's current Pretax Margin % of 17.78% is 264% above median its 10-year median of 4.89. The Medical Devices & Instruments industry median Pretax Margin % is 2.61. Xvivo Perfusion AB's value of 17.78% is 581.2% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #238 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #238 out of 817 companies for Pretax Margin %. This puts Xvivo Perfusion AB in the upper half of its industry. The industry median Pretax Margin % is 2.61. Xvivo Perfusion AB's value of 17.78% is 581.2% above this benchmark. While the company's 10-year median is 4.89 vs. the industry median of 2.61, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.61, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Pretax Margin % of 17.78% is 581.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Pretax Margin % is 17.78%, which is 264% above median its own 10-year median of 4.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Pretax Margin % is 17.78%, which is 264% above median its 10-year median of 4.89 and 581.2% above the Medical Devices & Instruments industry median of 2.61. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Pretax Margin % is 17.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Pretax Margin %: 17.78% (264% above median its 10-year median of 4.89)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 581.2% above the Medical Devices & Instruments median (#238 of 817)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
